Role of Anti-TREK-1 Antibodies in Sudden Cardiac Arrest Without Blockage
Part of Heart & circulation clinical trials.
This study looks for a specific type of antibody (called anti-TREK-1) in the blood of people who have had a sudden cardiac arrest without a clear cause. It aims to understand if these antibodies play a role in the condition, which might help with future diagnosis or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been diagnosed with sudden cardiac arrest without a blocked artery (called SCVF).
- You must agree to give written permission to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests medical treatments for people who survived a cardiac arrest with a specific heart rhythm problem called idiopathic ventricular fibrillation. If your cardiac arrest was likely from a heart issue but not from clogged arteries, you might help find better treatments.
This study looks at factors that may help predict sudden cardiac arrest in people with coronary artery disease. If you have a recent diagnosis of significant blockage or a heart attack, joining this trial could help improve risk assessment.
This study looks at how certain substances in your blood (called biomarkers) might help predict the risk of serious heart rhythm problems. By joining, you could help doctors better understand who needs treatment to prevent dangerous heart rhythms.
This study looks at how the heart's electrical signals can help doctors understand if treatments prevent dangerous heart rhythms in active people. It involves people with or without heart devices like ICDs or pacemakers, and may help improve care for active individuals with heart conditions.
This study is for people with coronary artery disease (blocked arteries in the heart) who live in the Pirkanmaa area of Finland. It will collect information and blood samples to better understand heart disease and sudden cardiac arrest.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
Hear when a new Short-coupled Ventricular Fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.